Optimal Strategies for Managing Adverse Events with GPRC5D Bispecifics in Multiple Myeloma : Episode 1
Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.
Now Viewing
EP: 1.Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
EP: 2.Adverse Event Management with BCMA Therapy
EP: 3.GPRC5D Therapy: Unique Challenges in Adverse Event Management
EP: 4.Overview of Long-term Follow-up from MonumenTAL-1
EP: 5.Overview of Other GPRC5D Therapy Clinical Trials
EP: 6.Administration and Dosing Management
EP: 7.Clinical Perspective on AE Tolerance
EP: 8.Clinical Experience in Managing AEs in GPRC5D Therapy
EP: 9.Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
EP: 10.Insights on REMS Programs and Strategies for Effective Patient Care
EP: 11.Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy
EP: 12.Adverse Event Management Strategies in GPRC5D Therapy
EP: 13.Clinical Scenario: AE Management for Bispecific Therapy in R/R MM
Video content above is prompted by the following:
- Discuss the long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
